← Russell 3000 cross-section

HUMA Humacyte, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-12, not restated
Healthcare

Scale

Market cap
$194m
Revenue TTM
$2m
Net income TTM
$-97m
Free cash flow
$-98m
Composite score
34.7
Sector rank
#2887

Valuation

P / E
EV / EBITDA
EV / sales
70.7
FCF yield
-50.41%
Earnings yield vs 10-yr
-54.70pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-4,560.8%
EBITDA margin
-4,990.0%
ROE
-309.4%
ROIC
Revenue growth
159.3%

Insider activity, last 90 days

Net open-market
$0.02m
Buyers
1
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Prior to the recent commercialization of the ATEVs in the vascular trauma indication, all of our revenue was derived from government and other grants. During the three and six months ended June 30, 2026, we generated $0.4 million and $0.9 million, respectively, in product revenue from sales of Symvess, compared with $0.1 million and $0.2 million, respectively, for the three and six months ended June 30, 2025. These increases are expected to include increased employee-related expenses, increased sales and marketing expenses, and increased director and officer insurance premiums, audit and legal fees, and expenses for compliance with public company reporting requirements under the Exchange Act …Humacyte, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-12

Read the full passage →